15-Deoxy-Δ^12,14-prostaglandin J₂ as a potential regulator of bone metabolism via PPARγ-dependent and independent pathways: a review

References

• Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285:25103–25108. doi:10.1074/jbc.R109.04108720501658
   PubMed Web of Science ®Google Scholar
• Wan Y. PPARgamma in bone homeostasis. Trends Endocrinol Metab. 2010;21:722–728. doi:10.1016/j.tem.2010.08.00620863714
   PubMed Web of Science ®Google Scholar
• Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13:791–801. doi:10.1038/nm159317618270
   PubMed Web of Science ®Google Scholar
• Ali D, Abuelreich S, Alkeraishan N, et al. Multiple intracellular signaling pathways orchestrate adipocytic differentiation of human bone marrow stromal stem cells. Biosci Rep. 2018;38(1). doi:10.1042/BSR20171252.
   PubMed Web of Science ®Google Scholar
• Abdallah BM, Alzahrani AM, Kassem M. Secreted clusterin protein inhibits osteoblast differentiation of bone marrow mesenchymal stem cells by suppressing ERK1/2 signaling pathway. Bone. 2018;110:221–229. doi:10.1016/j.bone.2018.02.01829476977
   PubMed Web of Science ®Google Scholar
• Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 2013;92:860–867. doi:10.1177/002203451350030623906603
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000. doi:10.1161/ATVBAHA.110.20744921508345
   PubMed Web of Science ®Google Scholar
• Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev. 2001;21:185–210.11301410
   PubMed Web of Science ®Google Scholar
• Forman BM, Tontonoz P, Chen J, et al. 15-deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803–812.8521497
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83:813–819.8521498
   PubMed Web of Science ®Google Scholar
• Takada I, Kouzmenko AP, Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol. 2009;5:442–447. doi:10.1038/nrrheum.2009.13719581903
   PubMed Web of Science ®Google Scholar
• Viccica G, Francucci CM, Marcocci C. The role of PPARgamma for the osteoblastic differentiation. J Endocrinol Invest. 2010;33:9–12.20938219
   PubMedGoogle Scholar
• Kawai M. Adipose tissue and bone: role of PPARgamma in adipogenesis and osteogenesis. Horm Mol Biol Clin Investig. 2013;15:105–113. doi:10.1515/hmbci-2013-0036
   PubMedGoogle Scholar
• Kim KR, Kim HJ, Lee SK, et al. 15-deoxy-delta12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss. PLoS One. 2015;10:e0122764. doi:10.1371/journal.pone.012276425859665
   PubMed Web of Science ®Google Scholar
• Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol. 2005;114:100–109. doi:10.1016/j.clim.2004.09.00815639643
   PubMed Web of Science ®Google Scholar
• Ueno N, Murakami M, Tanioka T, et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem. 2001;276:34918–34927. doi:10.1074/jbc.M10042920011418589
   PubMed Web of Science ®Google Scholar
• Kunz T, Marklund N, Hillered L, et al. Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat. J Neurotrauma. 2002;19:1051–1064. doi:10.1089/08977150276034196512482118
   PubMed Web of Science ®Google Scholar
• Urade Y, Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat. 2002;68–69:375–382.
   PubMed Web of Science ®Google Scholar
• Bie Q, Dong H, Jin C, et al. 15d-PGJ2 is a new hope for controlling tumor growth. Am J Transl Res. 2018;10:648–658.29636856
   PubMed Web of Science ®Google Scholar
• Zhu F, Wang P, Kontrogianni-Konstantopoulos A, et al. Prostaglandin (PG)D(2) and 15-deoxy-Delta(12,14)-PGJ(2), but not PGE(2), mediate shear-induced chondrocyte apoptosis via protein kinase A-dependent regulation of polo-like kinases. Cell Death Differ. 2010;17:1325–1334. doi:10.1038/cdd.2010.1320150912
   PubMed Web of Science ®Google Scholar
• Shibata T, Kondo M, Osawa T, et al. 15-deoxy-delta 12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem. 2002;277:10459–10466. doi:10.1074/jbc.M11031420011786541
   PubMed Web of Science ®Google Scholar
• Shibata T. 15-deoxy-delta(1)(2),(1)(4)-prostaglandin J(2) as an electrophilic mediator. Biosci Biotechnol Biochem. 2015;79:1044–1049. doi:10.1080/09168451.2015.101214926011133
   PubMed Web of Science ®Google Scholar
• Kawahito Y, Kondo M, Tsubouchi Y, et al. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest. 2000;106:189–197. doi:10.1172/JCI965210903334
   PubMed Web of Science ®Google Scholar
• Ho TC, Chen SL, Yang YC, et al. 15-deoxy-delta(12,14)-prostaglandin J2 induces vascular endothelial cell apoptosis through the sequential activation of MAPKS and p53. J Biol Chem. 2008;283:30273–30288. doi:10.1074/jbc.M80419620018718914
   PubMed Web of Science ®Google Scholar
• Kim EH, Surh YJ. The role of 15-deoxy-delta(12,14)-prostaglandin J(2), an endogenous ligand of peroxisome proliferator-activated receptor gamma, in tumor angiogenesis. Biochem Pharmacol. 2008;76:1544–1553. doi:10.1016/j.bcp.2008.07.04318771658
   PubMed Web of Science ®Google Scholar
• Fu YG, Sung JJ, Wu KC, et al. Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J2 through the downregulation of angiopoietin-1. Cancer Lett. 2006;243:246–254. doi:10.1016/j.canlet.2005.11.03916412567
   PubMed Web of Science ®Google Scholar
• Murata T, Aritake K, Matsumoto S, et al. Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A. 2011;108:19802–19807. doi:10.1073/pnas.111001110822106279
   PubMed Web of Science ®Google Scholar
• Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385–396. doi:10.1196/annals.1365.03517308163
   PubMed Web of Science ®Google Scholar
• Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci. 2009;66:236–253. doi:10.1007/s00018-008-8429-z18854943
   PubMed Web of Science ®Google Scholar
• Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biochem. 2001;276:37731–37734. doi:10.1074/jbc.R100034200
   Web of Science ®Google Scholar
• Ge C, Zhao G, Li B, et al. Genetic inhibition of PPARγ S112 phosphorylation reduces bone formation and stimulates marrow adipogenesis. Bone. 2018;107:1–9. doi:10.1016/j.bone.2017.10.02329107124
   PubMed Web of Science ®Google Scholar
• Guan HP, Ishizuka T, Chui PC, et al. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev. 2005;19:453–461. doi:10.1101/gad.126330515681609
   PubMed Web of Science ®Google Scholar
• Zhu Y, Kan L, Qi C, et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biochem. 2000;275:13510–13516. doi:10.1074/jbc.275.18.13510
   Web of Science ®Google Scholar
• Lefterova MI, Lazar MA. New developments in adipogenesis. Trends Endocrinol Metab. 2009;20:107–114. doi:10.1016/j.tem.2008.11.00519269847
   PubMed Web of Science ®Google Scholar
• Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005;437:759–763. doi:10.1038/nature0398816127449
   PubMed Web of Science ®Google Scholar
• Yamashita D, Yamaguchi T, Shimizu M, et al. The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells. 2004;9:1017–1029. doi:10.1111/j.1365-2443.2004.00786.x15507114
   PubMed Web of Science ®Google Scholar
• Kawai M, Green CB, Lecka-Czernik B, et al. A circadian-regulated gene, nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci U S A. 2010;107:10508–10513. doi:10.1073/pnas.100078810720498072
   PubMed Web of Science ®Google Scholar
• Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635–2643. doi:10.1210/en.2007-027017395698
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19–39. doi:10.1016/j.gene.2004.06.04415474285
   PubMed Web of Science ®Google Scholar
• Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A. 2005;102:3324–3329. doi:10.1073/pnas.040874210215728361
   PubMed Web of Science ®Google Scholar
• Akune T, Ohba S, Kamekura S, et al. PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004;113:846–855. doi:10.1172/JCI20041990015067317
   PubMed Web of Science ®Google Scholar
• Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet (London, England). 2011;377:1276–1287. doi:10.1016/S0140-6736(10)62349-5
   PubMed Web of Science ®Google Scholar
• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet (London, England). 2002;359:1929–1936. doi:10.1016/S0140-6736(02)08761-5
   PubMed Web of Science ®Google Scholar
• Kim SW, Her SJ, Kim SY, et al. Ectopic overexpression of adipogenic transcription factors induces transdifferentiation of MC3T3-E1 osteoblasts. Biochem Biophys Res Commun. 2005;327:811–819. doi:10.1016/j.bbrc.2004.12.07615649418
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318–3325. doi:10.1172/JCI2707116322775
   PubMed Web of Science ®Google Scholar
• Moerman EJ, Teng K, Lipschitz DA, et al. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 2004;3:379–389. doi:10.1111/j.1474-9728.2004.00127.x15569355
   PubMed Web of Science ®Google Scholar
• Muruganandan S, Govindarajan R, Sinal CJ. Bone marrow adipose tissue and skeletal health. Curr Osteoporos Rep. 2018;16(4):434–442. doi:10.1007/s11914-018-0451-y29855795
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77:289–312. doi:10.1146/annurev.biochem.77.061307.09182918518822
   PubMed Web of Science ®Google Scholar
• Miyanishi K, Yamamoto T, Irisa T, et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone. 2002;30:185–190.11792583
   PubMed Web of Science ®Google Scholar
• Yin L, Li YB, Wang YS. Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures: mechanism of steroid-induced osteonecrosis. Chin Med J. 2006;119:581–588.16620700
   PubMed Web of Science ®Google Scholar
• Li X, Jin L, Cui Q, et al. Steroid effects on osteogenesis through mesenchymal cell gene expression. Osteoporos Int. 2005;16:101–108. doi:10.1007/s00198-004-1649-715205891
   PubMed Web of Science ®Google Scholar
• Guo L, Chen K, Yuan J, et al. Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARgamma and APC. J Cell Physiol. 2018;234:581–594. doi:10.1002/jcp.26788
   Web of Science ®Google Scholar
• Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209–257. doi:10.1196/annals.1402.08918056045
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–342. doi:10.1038/nature0165812748652
   PubMed Web of Science ®Google Scholar
• Kwak HB, Jin HM, Ha H, et al. Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1). Biochem Biophys Res Commun. 2005;330:1080–1086. doi:10.1016/j.bbrc.2005.03.08515823554
   PubMed Web of Science ®Google Scholar
• Hounoki H, Sugiyama E, Mohamed SG, et al. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression. Bone. 2008;42:765–774. doi:10.1016/j.bone.2007.11.01618242157
   PubMed Web of Science ®Google Scholar
• Cappellen D, Luong-Nguyen NH, Bongiovanni S, et al. Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biochem. 2002;277:21971–21982. doi:10.1074/jbc.M200434200
   Web of Science ®Google Scholar
• Giri S, Rattan R, Singh AK, Singh I. The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. J Immunol. 2004;173:5196–5208.15470065
   PubMed Web of Science ®Google Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–361. doi:10.1038/nature0166112748655
   PubMed Web of Science ®Google Scholar
• Park JY, Pillinger MH, Abramson SB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol. 2006;119(3):229–240. doi:10.1016/j.clim.2006.01.01616540375
   PubMed Web of Science ®Google Scholar
• Tsubouchi Y, Kawahito Y, Kohno M, et al. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-delta(12,14)-prostaglandin J2. Biochem Biophys Res Commun. 2001;283:750–755. doi:10.1006/bbrc.2001.484711350047
   PubMed Web of Science ®Google Scholar
• Wada K, Nakajima A, Blumberg RS. PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn’s disease. Trends Mol Med. 2001;7:329–331.11516972
   PubMed Web of Science ®Google Scholar
• Nakajima A, Wada K, Miki H, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology. 2001;120:460–469.11159886
   PubMed Web of Science ®Google Scholar
• Reilly CM, Oates JC, Cook JA, et al. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol. 2000;164:1498–1504.10640767
   PubMed Web of Science ®Google Scholar
• Combs CK, Johnson DE, Karlo JC, et al. Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000;20:558–567.10632585
   PubMed Web of Science ®Google Scholar
• Cheron A, Peltier J, Perez J, et al. 15-deoxy-delta12,14-prostaglandin J2 inhibits glucocorticoid binding and signaling in macrophages through a peroxisome proliferator-activated receptor gamma-independent process. J Immunol. 2004;172:7677–7683.15187150
   PubMed Web of Science ®Google Scholar
• Paakinaho V, Kaikkonen S, Levonen AL, et al. Electrophilic lipid mediator 15-deoxy-delta12,14-prostaglandin j2 modifies glucocorticoid signaling via receptor SUMOylation. Mol Cell Biol. 2014;34:3202–3213. doi:10.1128/MCB.00748-1424980431
   PubMed Web of Science ®Google Scholar
• Oh KS, Patel H, Gottschalk RA, et al. Anti-inflammatory chromatinscape suggests alternative mechanisms of glucocorticoid receptor action. Immunity. 2017;47(2):298–309.e295. doi:10.1016/j.immuni.2017.07.01228801231
   PubMed Web of Science ®Google Scholar
• Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer. 2000;88:2892–2898.10898330
   PubMedGoogle Scholar
• Suva LJ, Washam C, Nicholas RW, et al. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7:208–218. doi:10.1038/nrendo.2010.22721200394
   PubMed Web of Science ®Google Scholar
• Bendre M, Gaddy D, Nicholas RW. et al. Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res.2003:S39–S45. doi:10.1097/01.blo.0000093844.72468.f414600591
   PubMed Web of Science ®Google Scholar
• Karaplis AC, Goltzman D. PTH and PTHrP effects on the skeleton. Rev Endocr Metab Disord. 2000;1:331–341. doi:10.1023/A:102652670389811706747
   PubMedGoogle Scholar
• Trouvin AP, Goëb V. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging. 2010;5:345–354. doi:10.2147/CIA.S1015321228900
   PubMed Web of Science ®Google Scholar
• Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem. 2002;277:24571–24578. doi:10.1074/jbc.M20256120011964407
   PubMed Web of Science ®Google Scholar
• Safina A, Sotomayor P, Limoge M, Morrison C, Bakin AV. TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol Cancer Res. 2011;9:1042–1053. doi:10.1158/1541-7786.MCR-10-019621700681
   PubMed Web of Science ®Google Scholar
• Vaamonde-Garcia C, Malaise O, Charlier E, et al. 15-deoxy-Δ-12, 14-prostaglandin J2 acts cooperatively with prednisolone to reduce TGF-β-induced pro-fibrotic pathways in human osteoarthritis fibroblasts. Biochem Pharmacol. 2019. doi:10.1016/j.bcp.2019.03.039
   Web of Science ®Google Scholar
• D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol. 2019;15:004. doi:10.1016/j.jbo.2018.10.00430937279
   PubMed Web of Science ®Google Scholar
• Sousa S, Clézardin P. Bone-targeted therapies in cancer-induced bone disease. Calcif Tissue Int. 2018;102:227–250. doi:10.1007/s00223-017-0353-529079995
   PubMed Web of Science ®Google Scholar
• Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007;26:1–18. doi:10.1089/dna.2006.050517263592
   PubMed Web of Science ®Google Scholar
• Kitz K, Windischhofer W, Leis HJ, et al. 15-deoxy-delta12,14-prostaglandin J2 induces cox-2 expression in human osteosarcoma cells through MAPK and EGFR activation involving reactive oxygen species. Free Radic Biol Med. 2011;50:854–865. doi:10.1016/j.freeradbiomed.2010.12.03921236332
   PubMed Web of Science ®Google Scholar
• Masi L, Recenti R, Silvestri S, et al. Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol. 2007;15:70–76. doi:10.1097/01.pai.0000213131.63417.fa17536311
   PubMedGoogle Scholar
• Lee EJ, Choi EM, Kim SR, et al. Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. Exp Mol Med. 2007;39:469–476. doi:10.1038/emm.2007.5117934334
   PubMed Web of Science ®Google Scholar
• Cheng L, Wang C, Jing J. Polo-like kinase 1 as a potential therapeutic target for osteosarcoma. Curr Pharm Des. 2015;21:1347–1350.25345614
   PubMed Web of Science ®Google Scholar
• Yen CC, Hsiao CD, Chen WM, et al. Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition. Oncotarget. 2014;5:716–725. doi:10.18632/oncotarget.170424566468
   PubMedGoogle Scholar
• Li X, Cui Q, Kao C, et al. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone. 2003;33:652–659.14555271
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Y, Zhang H, et al. Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARgamma expression and activating Wnt signaling pathway. Exp Biol Med (Maywood, NJ). 2014;239:347–355. doi:10.1177/1535370213519215
   PubMed Web of Science ®Google Scholar
• Yang YJ, Zhu Z, Wang DT, et al. Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPARgamma2 signaling in GIO rats. Acta Pharmacol Sin. 2018;39:633–641. doi:10.1038/aps.2017.13429323335
   PubMed Web of Science ®Google Scholar